Roth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target following Q3 results reported on Tuesday.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

BioLineRx (BLRX) Tops Q3 EPS by 4cNovember 22, 2016 8:07 AM Form 6-K BioLineRx Ltd. For: Nov 22November 22, 2016 8:01 AM BioLineRx Reports Third Quarter 2016 Financial ResultsNovember 22, 2016 8:00 AM BioLineRx (BLRX) Enters In-Licensing Agreement for Anti-Inflammatory DES Treatment November 21, 2016 7:06 AM